365219-92-7 Usage
Uses
Used in Pharmaceutical Industry:
1-((4R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethanol is used as a therapeutic agent for the treatment of cardiovascular diseases. Its application is based on its potential to exhibit beneficial effects on the cardiovascular system, although further research is needed to confirm its efficacy and safety.
Additionally, 1-((4R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethanol is used as an anti-inflammatory agent. The application is due to its possible ability to reduce inflammation and alleviate symptoms associated with various inflammatory conditions. However, more research is necessary to establish its effectiveness and safety in this context.
Overall, 1-((4R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)ethanol shows promise for potential use in drug development, particularly in the treatment of cardiovascular diseases and as an anti-inflammatory agent. Further investigation is warranted to explore its potential applications and establish its effectiveness and safety in medicinal use.
Check Digit Verification of cas no
The CAS Registry Mumber 365219-92-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,5,2,1 and 9 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 365219-92:
(8*3)+(7*6)+(6*5)+(5*2)+(4*1)+(3*9)+(2*9)+(1*2)=157
157 % 10 = 7
So 365219-92-7 is a valid CAS Registry Number.
365219-92-7Relevant academic research and scientific papers
Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors
Wada,Holms,Curtin,Dai,Florjancic,Garland,Guo,Heyman,Stacey,Steinman,Albert,Bouska,Elmore,Goodfellow,Marcotte,Tapang,Morgan,Michaelides,Davidsen
, p. 219 - 232 (2007/10/03)
A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1′ substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a.highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.
Process for the selective N-formylation of N-hydroxylamines
-
Example 4, (2010/01/30)
The instant invention provides a process for the selective N-formylation of N-hydroxylamines.
